Correlation Between Ikena Oncology and Ovid Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Ovid Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Ovid Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ikena Oncology and Ovid Therapeutics, you can compare the effects of market volatilities on Ikena Oncology and Ovid Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Ovid Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Ovid Therapeutics.

Diversification Opportunities for Ikena Oncology and Ovid Therapeutics

0.93
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Ikena and Ovid is 0.93. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Ovid Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ovid Therapeutics and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Ovid Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ovid Therapeutics has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Ovid Therapeutics go up and down completely randomly.

Pair Corralation between Ikena Oncology and Ovid Therapeutics

Given the investment horizon of 90 days Ikena Oncology is expected to generate 0.42 times more return on investment than Ovid Therapeutics. However, Ikena Oncology is 2.38 times less risky than Ovid Therapeutics. It trades about -0.23 of its potential returns per unit of risk. Ovid Therapeutics is currently generating about -0.2 per unit of risk. If you would invest  148.00  in Ikena Oncology on December 2, 2024 and sell it today you would lose (14.00) from holding Ikena Oncology or give up 9.46% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Ikena Oncology  vs.  Ovid Therapeutics

 Performance 
       Timeline  
Ikena Oncology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Ovid Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Ovid Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Ikena Oncology and Ovid Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ikena Oncology and Ovid Therapeutics

The main advantage of trading using opposite Ikena Oncology and Ovid Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Ovid Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ovid Therapeutics will offset losses from the drop in Ovid Therapeutics' long position.
The idea behind Ikena Oncology and Ovid Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators